ReviewEuropean journal of haematology2026
Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment.
Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Frailty Assessment in Older Adults With Acute Myeloid Leukemia: From Treatment Eligibility to Treatment Adaptation.European journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low-dose cytarabine, hydroxyurea, or supportive care, with poor outcomes. The introduction of hypomethylating agents combined with Venetoclax and the availability of targeted therapies have expanded therapeutic possibilities, challenging the notion that elderly AML is uniformly incurable. In this evolving context, accurate assessment of fitness and frailty is essential to guide treatment decisions. This review summarizes current concepts of frailty in older AML patients, including general geriatric tools and hematology-specific indices. It discusses the role of Comprehensive Geriatric Assessment, frailty phenotypes, and comorbidity scores such as the transplantation-specific comorbidity index and the Charlson index, alongside AML-focused tools like the Ferrara criteria and integrated molecular risk models. Most existing tools were developed in intensively treated cohorts, and their applicability to patients receiving non-intensive regimens remains uncertain. Fitness is increasingly recognized as a dynamic, multidimensional construct incorporating clinical, functional, cognitive, social, and biological factors. A multiparametric approach is proposed, integrating these variables into decision-making models, potentially enhanced by artificial intelligence to optimize treatment selection in older AML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.